Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Breast Cancer Research and Treatment

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10549-016-4059-6PMID 27888421
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas.

  2016cited by this paper
• Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer.

  2016cited by this paper
• Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.

  2016cited by this paper
• Clinical implications of molecular heterogeneity in triple negative breast cancer.

  2015cited by this paper
• Evaluation of the stage IB designation of the American Joint Committee on Cancer staging system in breast cancer.

  2015cited by this paper
• Androgen Receptor Expression Predicts Decreased Survival in Early Stage Triple-Negative Breast Cancer

  2014cited by this paper
• Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

  2014cited by this paper
• Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network

  2012cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system.

  2011cited by this paper
• Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer

  2011cited by this paper
• Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

  2011cited by this paper
• Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

  2011cited by this paper
• Triple-Negative Breast Cancer: Role of the Androgen Receptor

  2010cited by this paper
• Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

  2010cited by this paper
• Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.

  2010cited by this paper
• A review of triple-negative breast cancer.

  2010cited by this paper
• Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.

  2010cited by this paper
• Triple-negative breast cancer.

  2010cited by this paper
• The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM

  2010cited by this paper
• Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

  2009cited by this paper
• Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.

  2008cited by this paper
• Epidemiology of basal-like breast cancer

  2008cited by this paper
• Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence

  2007cited by this paper
• TNM: principles, history, and relation to other prognostic factors.

  2001cited by this paper

• Potential and Applications of Mn Complexes in Breast Cancer

  2026cites this paper
• Extracellular Vesicles as Emerging Drug Delivery Platforms in Triple-Negative Breast Cancer: A Systematic Review

  2026cites this paper
• Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC.

  2026cites this paper
• Sacituzumab govitecan as a therapeutic breakthrough in the treatment of triple-negative breast cancer: a systematic review of clinical trials

  2026cites this paper
• Receipt of guideline‐concordant local and chemotherapy‐based systemic therapy for patients with triple‐negative breast cancer: 10‐year survival outcomes in a multi‐state population‐based analysis

  2026cites this paper
• A comparative analysis of mutational profiles between triple-negative breast cancer and non-triple-negative breast cancer

  2026cites this paper
• Programmable local immunochemotherapy for triple-negative breast cancer via spatiotemporally controlled release of CpG oligodeoxynucleotides, gemcitabine, and paclitaxel.

  2026cites this paper
• Personalized mRNA vaccine induces strong, durable immunity in hard-to-treat breast cancer.

  2026cites this paper
• Pembrolizumab for Early-Stage Triple-Negative Breast Cancer: KEYNOTE-522 Japan Subgroup Analysis.

  2026cites this paper
• Ultrasound-based radiomics for the evaluation of breast cancer

  2026cites this paper
• Anthropometric Characteristics of Triple-Negative Breast Cancer Patients by Menopausal Status: Evidence from the Population-Based Multicentric Study—MCC-Spain

  2026cites this paper
• Preclinical Study of CDH3-Targeted 89Zr/177Lu Theranostics in Triple-Negative Breast Cancer

  2026cites this paper
• Experimental animal models of chemically induced breast cancer: An update

  2026cites this paper
• Molecular and Clinicopathological Biomarkers Predicting Brain Metastasis in Triple-Negative Breast Cancer: A Systematic Review.

  2026cites this paper
• Patterns of presentation, treatment, and survival among older adults with metastatic breast cancer: Results from a large prospective registry.

  2025cites this paper
• Targeting TRPML3 inhibits proliferation and invasion, and enhances doxorubicin sensitivity by disrupting lysosomal acidification and mitochondrial function in triple-negative breast cancer.

  2025cites this paper
• Programmed Design of Nitric Oxide and Photodynamic Therapy Based on Orthogonal Upconversion Nanoparticles Improves Anti‐Tumor Efficacy via Protein S‐nitrosylation

  2025cites this paper
• EYA3 regulation of NF-κB and CCL2 suppresses cytotoxic NK cells in the premetastatic niche to promote TNBC metastasis

  2025cites this paper
• Targeting Extra Domain A of Fibronectin to Improve Noninvasive Detection of Triple-Negative Breast Cancer

  2025cites this paper
• Iron-Dependent Cell Death: Exploring Ferroptosis as a Unique Target in Triple-Negative Breast Cancer Management

  2025cites this paper
• Inhibition of ATG5-mediated autophagy maintains PMAIP1 stability to promote cell apoptosis and suppress triple-negative breast cancer progression

  2025cites this paper
• Ferroptosis-related genes as prognostic markers for survival and immunotherapy in triple-negative breast cancer: analysis of public databases and a single institution

  2025cites this paper
• Molecular genetic predictors of progression of triple negative breast cancer

  2025cites this paper
• Radionuclide-based nanotechnologies in triple-negative breast cancer: current evidence and future perspectives

  2025cites this paper
• The clinicopathological features of breast cancer in Peutz-Jeghers syndrome: results from an international survey

  2025cites this paper
• Ratio of T-cell Subsets Predicts Prognosis in Triple-Negative Breast Cancer Patients

  2025cites this paper
• Honokiol in the treatment of triple-negative breast cancer: a network pharmacology approach and experimental validation.

  2025cites this paper
• Antimigratory and Antiproliferative Effects of the Brain‐Targeted Peptide Conjugate PepH3‐vCPP2319 on Triple Negative Breast Cancer Cell Cultures

  2025cites this paper
• KIF20A promotes triple-negative breast cancer progression via activation of the IL-17 signaling pathway.

  2025cites this paper
• Homologous targeted neutrophils-liposome system for pyroptosis-enhanced antitumor immunotherapy of triple-negative breast cancer

  2025cites this paper
• Molecular profiling of breast cancer methylation pattern in triple negative versus non- triple negative breast cancer

  2025cites this paper
• Glandular Tissue Component on Breast Ultrasound: Association with Survival Outcomes in Women with Invasive Breast Cancer.

  2025cites this paper
• Organ-targeted drug delivery systems (OTDDS) of poly[(N-acryloylglycine)-co-(N-acryloyl-L-phenylalanine methyl ester)] copolymer library and effective treatment of triple-negative breast cancer.

  2025cites this paper
• Modulation of Wnt/Beta-Catenin Pathway by Major Dietary Phytochemicals Against Breast Cancer Development

  2025cites this paper
• Targeting stemness pathways modulates macrophage polarization and reprograms the tumor microenvironment

  2025cites this paper
• Real-World Neoadjuvant Systemic Therapy Utilization and Treatment Patterns in Patients with Early-Stage or Locally Advanced Triple-Negative Breast Cancer in Greece—The TRINITY Study

  2025cites this paper
• Identifying risk factors for poor prognosis and developing prognostic model in patients achieving pathological complete response after neoadjuvant therapy for breast cancer

  2025cites this paper
• OTUD4-ZMYND8-DDX3X Axis Drives Immunosuppressive Microenvironment in Spinal Metastases of Triple-Negative Breast Cancer

  2025cites this paper
• Predictive markers of rapid disease progression and chemotherapy resistance in triple-negative breast cancer patients following postoperative adjuvant therapy

  2025cites this paper
• Association of Structural Maintenance of Chromosome-1A Phosphorylation with Progression of Breast Cancer

  2025cites this paper
• Whole genome sequencing powered ctDNA sequencing for breast cancer detection.

  2025cites this paper
• ELK3-CYFIP2 axis-mediated actin remodeling modulates metastasis and natural killer cell responses in triple-negative breast cancer

  2025cites this paper
• Artificial Intelligence and Breast Cancer Management: From Data to the Clinic

  2025cites this paper
• Significance of the monocyte CCR2-CCL2 axis in triple-negative breast cancer.

  2025cites this paper
• NONO interacts with nuclear PKM2 and directs histone H3 phosphorylation to promote triple-negative breast cancer metastasis

  2025cites this paper
• Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61-20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial.

  2025cites this paper
• Prognostic value of the HALP score in breast cancer: a systematic review and meta-analysis

  2025cites this paper
• Molecular Subtypes and Survival Patterns in Female Breast Cancer: Insights from a 12-Year Cohort

  2025cites this paper
• Advanced and Metastatic Triple Negative Breast Cancer—Potential New Treatment

  2025cites this paper
• Potentiating Antibody-Dependent Cellular Cytotoxicity in Triple-Negative Breast Cancer via the Humanized Anti-CD147 Antibody

  2025cites this paper
• Reference-free RNA profiling predicts triple negative breast cancer chemoresistance to neoadjuvant treatment

  2025cites this paper
• First mammogram-detected cancers portend worse survival in young women diagnosed with breast cancer

  2025cites this paper
• The predictive effect of the CD155-TIGIT immune checkpoint axis complex on neoadjuvant chemotherapy efficacy in triple-negative breast cancer: A preliminary study

  2025cites this paper
• The new era of immunotherapy for breast cancer: challenges and coping strategies of CAR-T cell therapy

  2025cites this paper
• The association between young age at metastatic breast cancer diagnosis and overall survival in the EMBRACE study

  2025cites this paper
• Deep learning for survival prediction in triple-negative breast cancer: development and validation in real-world cohorts

  2025cites this paper
• Binding Interaction and Stability Analysis of Quercetin and its Derivatives as Potential Inhibitors of Triple Negative Breast Cancer (TNBC) against PARP1 Protein: An in-silico Study.

  2025cites this paper
• Treatment patterns and outcomes in HER2-low metastatic breast cancer patients previously treated with chemotherapy: a US real-world cohort study

  2025cites this paper
• Low-GPX4 drives a sustained drug-tolerant persister state in TNBC by a targetable adaptive FSP1 upregulation

  2025cites this paper
• Clinical Significance of HER2-low Expression in Triple-negative Breast Cancer: A Retrospective Multicenter Study

  2025cites this paper
• Multi-omics profile of exceptional long-term survivors of AJCC stage III triple-negative breast cancer.

  2025cites this paper
• Beta-cyclodextrin formulation of a disulfide-bond disrupting agent for improved systemic exposure

  2025cites this paper
• Effects of gut microbiota in breast cancer

  2025cites this paper
• Breast cancer spine metastases treated with stereotactic body radiation therapy: patient outcomes and predictors

  2025cites this paper
• Triple-Negative Breast Cancer on the Rise: Breakthroughs and Beyond

  2025cites this paper
• Chemotherapeutic drug scavenger-based combination therapy toward treating triple-negative breast cancer

  2025cites this paper
• Piperidine and valproic acid hybrid compound (F2S4-p-VPA) outperforms methotrexate as anti-proliferative and cells migration inhibition

  2025cites this paper
• Neoadjuvant Chemotherapy is Not Associated with Improved Overall Survival in Metaplastic Breast Cancer Regardless of Tumor Subtype

  2025cites this paper
• Blood transfusion mediated tumor microenvironment remodeling in breast cancer.

  2025cites this paper
• Roles and Prospective Applications of Ferroptosis Suppressor Protein 1 (FSP1) in Malignant Tumor Treatment

  2025cites this paper
• Clinical Benefit of Adjuvant Capecitabine According To Residual Cancer Burden in Patients With Triple-Negative Breast Cancer With Residual Disease Following Neoadjuvant Chemotherapy.

  2025cites this paper
• The FSIP Family: Roles in Health and Cancer

  2025cites this paper
• Integrating multimodal ultrasound imaging and machine learning for predicting luminal and non-luminal breast cancer subtypes

  2025cites this paper
• Therapeutic Potential of Metal-Based and PARP Inhibitor Chemotherapy for BRCA1-Associated Triple-Negative Breast Cancer

  2025cites this paper
• Mapping cell-cell fusion at single-cell resolution

  2025cites this paper
• Electrochemical sensor medical diagnosis assisted simulation LINC00115 exerts oncogenic function in triple negative breast cancer via regulation of TM9SF

  2025cites this paper
• Interconnected axes of phenotypic plasticity drive coordinated cellular behaviour and worse clinical outcomes in breast cancer

  2025cites this paper
• Alexidine is a TAZ-specific small-molecule inhibitor that suppresses breast cancer invasion and metastasis

  2025cites this paper
• Chemoimmunomodulation in triple negative breast cancer: a key to maximizing anti-PD-1 chemoimmunotherapeutic efficacy

  2025cites this paper
• CRYβB2 alters cell adhesion to promote invasion in a triple-negative breast cancer cell line

  2025cites this paper
• Dendritic cells in triple-negative breast cancer: From pathophysiology to therapeutic applications.

  2025cites this paper
• Triple-Negative Breast Cancer Progression and Drug Resistance in the Context of Epithelial–Mesenchymal Transition

  2025cites this paper
• Novel Strategy of Antibody Affinity Maturation and Enhancement of Nucleolin‐Mediated Antibody‐Dependent Cellular Cytotoxicity Against Triple‐Negative Breast Cancer

  2025cites this paper
• Advances in Ultrasound-Targeted Microbubble Destruction (UTMD) for Breast Cancer Therapy

  2025cites this paper
• Tumour cell-induced platelet aggregation in breast cancer: Scope of metal nanoparticles.

  2025cites this paper
• Anti-TNBC effects of Lappaol F by targeting epithelial-mesenchymal transition via regulation of GSK-3β/YAP/β-catenin and PI3K/AKT pathways

  2025cites this paper
• Impact of adjuvant chemotherapy delay on overall survival in early-stage breast cancer: a retrospective analysis

  2025cites this paper
• Prognostic significance of androgen receptor expression in triple-negative breast cancer

  2025cites this paper
• Overall Survival and Economic Impact of Triple-Negative Breast Cancer in Brazilian Public Health Care: A Real-World Study

  2025cites this paper
• Defective X-chromosome inactivation and cancer risk in women

  2025cites this paper
• Ubiquitin D Promotes Lung Metastasis by Stabilizing MMP3 in Triple-Negative Breast Cancer

  2025cites this paper
• Constructing a novel prognostic model for triple-negative breast cancer based on genes associated with vasculogenic mimicry

  2024cites this paper
• CircTRIM1 encodes TRIM1-269aa to promote chemoresistance and metastasis of TNBC via enhancing CaM-dependent MARCKS translocation and PI3K/AKT/mTOR activation

  2024cites this paper
• Whole Genome Sequencing of Enterococcus faecalis Isolated from Stool Sample of a Postmenopausal Women with Breast Cancer Patient in Malaysia

  2024cites this paper
• Prognostic Values of CD8+, PARP, and EGFR on Overall Survival in Patients with Triple-Negative Breast Cancer

  2024cites this paper
• Targeting Interleukin-13 Receptor α2 and EphA2 in Aggressive Breast Cancer Subtypes with Special References to Chimeric Antigen Receptor T-Cell Therapy

  2024cites this paper
• Electroporation enhances cell death in 3D scaffold-based MDA-MB-231 cells treated with metformin.

  2024cites this paper
• What is the future of immune checkpoints inhibitors for metastatic triple negative breast cancers?

  2024cites this paper
• Retrospective Observational Study to Determine the Epidemiology and Treatment Patterns of Patients with Triple-Negative Breast Cancer

  2024cites this paper
• Real-world overall survival and characteristics of patients with ER-zero and ER-low HER2-negative breast cancer treated as triple-negative breast cancer: a Swedish population-based cohort study

  2024cites this paper